Abstract: A novel polyamine derivative, or polyol derivative, having a piperidylaminotriazine skeleton; salts of such compounds; a process for producing them; an organic material stabilizer comprising any of such compounds; a method of stabilizing an organic material; and a stabilized organic material. Compounds of the general formula: (1) (wherein X is N(R4) or an oxygen atom; R1 is an n-valent hydrocarbon group; R2 is a hydrogen atom or an alkyl; R3 is a hydrogen atom, an alkyl, an alkoxy or an acyl; R4 is a hydrogen atom or an alkyl; and n is an integer of 3 to 16) are effective in the stabilization of an organic material against deterioration by light, heat, oxygen, ozone and electromagnetic waves, such as X-rays and ?-rays.

Abstract: Compounds of Formula I wherein the substituents are as defined in claim 1, and the agrochemically acceptable salts and all stereoisomers and tautomeric forms of the compounds of formula I can be used as agrochemical active ingredients and can be prepared in a manner known per se.

Abstract: Disclosed are compounds of Formula 1, N-oxides, and salts thereof, wherein R1, R2, R9a, R9b, G, W, X, Y, and Z are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling plant disease caused by a fungal pathogen comprising applying an effective amount of a compound or a composition of the invention.

Abstract: The present invention relates to chemical compounds having a general formula I wherein A1, A2, C1, C2, D, L1, L2, Z and R3, R4, R6, R7 and R8 are defined herein, which are capable of modulating Aurora kinase protein activity, thereby influencing various disease states and conditions related to the activities of Aurora kinase proteins. For example, the compounds are capable of influencing the process of cell cycle and cell proliferation to treat cancer and cancer-related diseases. The invention also includes pharmaceutical compositions, processes of preparing compounds of the invention, synthetic intermediates and methods of treatment of conditions related to the activity of Aurora kinase.

Abstract: The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme. Specifically, the invention is directed to compounds according to Formula I: wherein R1, R2, R3, R5a, R6a A, B, Y, x, and m are defined below, and to pharmaceutically-acceptable salts thereof. The compounds of the invention are sEH inhibitors and can be used in the treatment of diseases mediated by the sEH enzyme, such as hypertension. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting sEH and treatment of conditions associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Abstract: The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme.

Abstract: The invention relates to a cosmetic composition, particularly for hair care, and to a method for cosmetically treating keratin material, particularly the hair, using the compounds of Formula (I), where: —n=1, 2, 3, or 4; —R1, R?1, R2, and R?2 are H, —OH, —NRR?, or a C1-C18 carbon group capable of containing one or more heteroatoms selected from among O, S, and N; and —Z is a multivalent carbon radical optionally substitutable and/or interruptible by specific groupings, it being understood that said radical Z includes at least one heteroatom selected from among N, O, and S.

Abstract: The invention relates to triazine and pyrimidine derivatives having Formula (1) or (2), and methods for using such compounds. For example, the compounds of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of anaplastic lymphoma kinase (ALK) activity, c-ros oncogene (ROS), insulin-like growth factor (IGF-IR), and/or insulin receptor (InsR) or a combination thereof.

Abstract: The invention provides compounds that inhibit protein kinase CK2 activity (CK2 activity), and compositions containing such compounds.

Abstract: Compounds, pharmaceuticals, kits and methods are provided for use with DPP-IV and other S9 proteases that comprise a member selected from the group consisting of: wherein E is CH or N, Q is selected from the group consisting of CO, CS, SO, SO2, or C?NR4, and L, X, Z, R2 and R3 are as defined herein.

Abstract: Selected compounds are effective for prophylaxis and treatment of inflammation and inflammatory disorders, such as NIK-mediated disorders. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, inflammation and the like.

Abstract: There are described compounds of the formula (I) in which the respective substituents have the meanings given in the description. The compounds of the formula (I) can be used as herbicides and plant growth regulators.

Abstract: The present invention relates to novel processes for the preparation of sterically hindered amine ethers by the transformation of a corresponding oxo-piperidin to a hydroxy or amino substituted sterically hindered amine ether and the preparation of a N-propoxy or N-propenoxy substituted sterically hindered amine and some novel compounds obtainable by these processes. The compounds made by these processes are particularly effective in the stabilization of polymer compositions against harmful effects of light, oxygen and/or heat and as flame-retardants for polymers.

Abstract: The invention provides for Triazine derivatives and their use to modulate protein kinase activity in a variety of conditions and diseases.

Abstract: Pyrimidine derivatives, which are useful as VEGFR2 inhibitors are described herein. The described invention also includes methods of making such pyrimidine derivatives as well as methods of using the same in the treatment of hyperproliferative diseases.

Abstract: This invention is concerned with compounds of the formula wherein A, R1 to R5 and G are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

Abstract: The invention is based on the discovery that compounds of formula (I) possess unexpectedly high affinity for the A2a adenosine receptor, and can be useful as antagonists thereof for preventing and/or treating numerous diseases, including Parkinson's disease. In one embodiment, the invention features a compound of formula (I).

Abstract: An azaazulene compound is provided. The azaazulene compound has formula (I) shown below. Each variable in formula (I) is defined in the specification. The compound can be used to treat cancer. The invention also provides a method for treating cancer. The method includes administering to a subject in need thereof an effective amount of one or more azaazulene compounds of formula (I).

Abstract: The present invention relates to an organic light-emitting diode comprising at least one diphenylaminobis(phenoxy)triazine or at least one bis(diphenylamino)phenoxytriazine compound, to a light-emitting layer comprising at least one diphenylamino-bis(phenoxy)triazine or at least one bis(diphenylamino)phenoxytriazine compound, to the use of the aforementioned compounds as a matrix material, hole/exciton blocker material, electron/exciton blocker material, hole injection material, electron injection material, hole conductor material and/or electron conductor material, and to a device selected from the group consisting of stationary visual display units, mobile visual display units and illumination units comprising at least one inventive organic light-emitting diode.

Abstract: The present invention relates to a novel process for the preparation of a sterically hindered nitroxyl ether from the corresponding sterically hindered nitroxyl radical by reacting it with a carbonyl compound and a hydroperoxide. The compounds prepared by this process are effective stabilizers for polymers against harmful effects of light, oxygen and/or heat, as flame-retardants for polymers and as polymerization regulators.

Abstract: The invention relates to a stable secondary battery utilizing as active element the oxidation and reduction cycle of a sterically hindered nitroxide radical, which is bonded to a triazine structural element. Further aspects of the invention are a method for providing such a secondary battery, the use of the respective compounds as active elements in secondary batteries and selected novel nitroxide compounds as such.

Abstract: The present invention relates to a novel anthrapyridone compound represented by the following formula (1) (wherein, R1 represents a hydrogen atom, an alkyl group and the like, R2 represents a hydrogen atom, an alkyl group, a phenyl group, a phenoxy group and the like, R3 represents a hydrogen atom, or a methoxy group, X represents an anilino group which may have a substituent such as a sulfonic acid group; a naphthylamino group which may be substituted by a sulfonic acid group; a mono- or di-alkylamino group which may have a substituent such as a sulfonic acid group; an aralkylamino group; a cycloalkylamino group; a phenoxy group which may have a substituent such as a sulfonic acid; a hydroxy group; an amino group; and the like, Y represents a chlorine atom; a hydroxy group; an amino group; and the like) in free acid form, an ink composition containing the same and a colored article using the same, and images recorded by an ink for inkjet recording containing said compound have high vividness and exhibit

Abstract: The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme. Specifically, the invention is directed to compounds according to Formula I: wherein R1, R2, R3, R5a, R6a A, B, Y, x, and m are defined below, and to pharmaceutically-acceptable salts thereof. The compounds of the invention are sEH inhibitors and can be used in the treatment of diseases mediated by the sEH enzyme, such as hypertension. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting sEH and treatment of conditions associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Abstract: The present invention is directed to pyridazinone compounds of formula (I) and furan compounds of formula (II), pharmaceutical compositions of compounds of formula (I) and (II), kits containing these compounds, methods of syntheses, and a method of treatment of a proliferative disease in a subject by administration of a therapeutically effective amount of a compound of formulae (I) or (II). Both classes of compounds were identified through screening of a collection of small molecule libraries.

Abstract: The invention is directed to novel sEH inhibitors and their use in the treatment of diseases mediated by the sEH enzyme. Specifically, the invention is directed to compounds according to Formula I: wherein R1, R2, R5a, R6a, A, B, Y, I, and m are defined below, and to pharmaceutically-acceptable salts thereof. The compounds of the invention are sEH inhibitors and can be used in the treatment of diseases mediated by the sEH enzyme, such as hypertension. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting sEH and treatment of conditions associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

Abstract: The invention relates to the compounds of general formula (I): in which R1, R2, R3, R4, R5 and R6 are as defined in Claim 1. These compounds can be used in the treatment of pathological conditions associated with the insulin-resistance syndrome.

Abstract: The invention relates to triazines and the use thereof to inhibit lysophosphatidic acid acyltransferase ? (LPAAT-?) activity. The invention further relates to methods of treating cancer using said triazines. The invention also relates to methods for screening for LPAAT-? activity.

Abstract: One aspect of the invention is concerned with cannabimimetic pyrazole analogs. Another aspect of the invention is concerned with new and improved pyrazole analogs having high affinities and/or selectivities for the CB1 cannabinoid receptor. A further aspect of the invention is concerned with pharmaceutical preparations employing the inventive analogs and methods of administering therapeutically effective amounts of the inventive analogs to provide a physiological effect.

Abstract: Disclosed are a compound for an organic electroluminescent device (organic EL device) which is improved in luminous efficiency, fully secured of driving stability, and of simple constitution and an organic EL device using said compound. The compound for an organic EL device has two indolocarbazole skeletons each of which is bonded to an aromatic group or two skeletons similar thereto. The organic EL device comprises a light-emitting layer disposed between an anode and a cathode piled one upon another on a substrate and said light-emitting layer comprises a phosphorescent dopant and the aforementioned compound for an organic EL device as a host material.

Abstract: Disclosed are an organic electroluminescent device (organic EL device) which is improved in luminous efficiency, fully secured of driving stability, and of simple constitution and a compound useful for the fabrication of said organic EL device. The compound for the organic EL device has an indolocarbazole structure or a structure similar thereto in the molecule wherein an aromatic group is bonded to the nitrogen atom in the indolocarbazole. The organic EL device has a light-emitting layer disposed between an anode and a cathode piled one upon another on a substrate and said light-emitting layer comprises a phosphorescent dopant and the aforementioned compound for an organic electroluminescent device as a host material.

Abstract: A compound of formula (I), or tautomers, or stereoisomers, or solvates, or pharmaceutically acceptable salts thereof, wherein M1, M2, L1, L2, W1, W2, X1, X2, Y1, Y2, A, R5 and R5a are as defined herein for the for treatment of conditions treatable by the blockade of an epithelial sodium channel, particularly conditions benefiting from mucosal hydration.

Abstract: The present invention provides a compound which is useful as an inhibitor against the kinase activity of EML4-ALK fusion proteins and mutant EGFR proteins. As a result of extensive and intensive studies on compounds having an inhibitory effect against the kinase activity of EML4-ALK fusion proteins and mutant EGFR proteins, the inventors of the present invention have found that the di(arylamino)aryl compound of the present invention has inhibitory activity against the kinase activity of EML4-ALK fusion proteins and mutant EGFR proteins. This finding led to the completion of the present invention.

Abstract: A process of slowing down diffusion of an element or a compound through a fluoroplastic comprising the addition of a reactive additive having reactive groups that react with the element or compound. A process of preventing degradation of the fluoroplastics PVDF and ECTFE used in, or in connection with a reactor where chlorine dioxide is produced comprising mixing the fluoroplastic with a reactive additive having reactive groups. A diffusion resistant fluoroplastic which comprises a reactive additive having reactive groups that react with an element and/or compound to which the fluoroplastic is diffusion resistant. The use of a reactive additive having reactive groups as an additive in a fluoroplastic to prevent or slow down the diffusion of an element or a compound through the fluoroplastic.

Abstract: Oxetane-containing nucleosides, particularly non-reducing psiconucleoside oxetanes are described herein. Therapeutic application of these oxetane compounds toward the treatment of nucleoside analog related disorders such as disorders involving cellular proliferation and infection are also described.

Abstract: The present application relates to novel azabicyclic compounds, processes for their preparation, their use alone or in combinations for the treatment and/or prevention of diseases, and their use for producing medicaments for the treatment and/or prevention of diseases, especially for the treatment and/or prevention of cardiovascular disorders.

Abstract: A compound of formula (I), or stereoisomers or pharmaceutically acceptable salts thereof, formula (1), or stereoisomers or pharmaceutically acceptable salts thereof, wherein A, U1, U2, R1a, R1b, R2 and R3 have the meanings as indicated in the specification, are useful for treating conditions mediated by activation of the adenosine A2A receptor, especially inflammatory or obstructive airways diseases. Pharmaceutical compositions that contain the compounds and a process for preparing the compounds are also described.

Abstract: The present invention relates to an antibacterial agent, which comprises, as an active ingredient, a compound represented by the following general formula (1): or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to an anthrapyridone compound represented by the following formula (1): [wherein, R represents a hydrogen atom, an alkyl group, a hydroxy lower alkyl group, a cyclohexyl group or a (mono- or di-alkylamino) alkyl group, X represents a cross-linking group represented by the formula: —NH—(CH2)n-NH—??(201) (wherein, n is 2 to 8) and another cross-linking group, respectively] or a salt thereof, an magenta ink composition containing the anthrapyridone compound, and a colored product therewith; said compound has a hue having a high vividness suitable for inkjet recording, a recorded matter therewith has strong fastnesses particularly such as light fastness and ozone fastness, and the ink composition has an excellent storage stability, whereby said compound is useful as a magenta coloring matter suitable for inkjet recording.

Abstract: The present invention relates to an anthrapyridone compound represented by the following Formula (1) (wherein, R represents a hydrogen atom, an alkyl group, a hydroxy lower alkyl group, a cyclohexyl group, a mono- or dialkylaminoalkyl group or a cyano lower alkyl group, X represents a cross linking group, Y represents a phenoxy group having 1 or 2 carboxyl groups) in free acid form and a magenta ink composition comprising the same, and provides magenta coloring matter and a magenta ink composition which have hue with high vividness suitable for inkjet recording, gives good fastness to a recorded article and are excellent in storage stability.

Abstract: The invention relates to triazines and the use thereof to inhibit lysophosphatidic acid acyltransferase ? (LPAAT-?) activity. The invention further relates to methods of treating cancer using said triazines. The invention also relates to methods for screening for LPAAT-? activity.

Abstract: The present invention relates to cancer therapy and to novel anticancer agents having a mechanism of action which is quite specific. It also relates to novel chemical compounds as well as their therapeutic application in humans.

Abstract: Sterically hindered hydroxy substituted alkoxyamine stabilizer compounds are made water compatible via certain backbones with affinity towards water. The sterically hindered amines are for example of the formula (8)-(10) These compounds are particularly effective in stabilizing aqueous polymer systems against the deleterious effects of oxidative, thermal and actinic radiation. The compounds are effective for example in stabilizing water borne coatings, aqueous inks, aqueous ink jet media and photocured aqueous systems.

Abstract: A compound of formula (1), or a pharmaceutically acceptable salt, solvate or in vivo hydrolysable ester thereof: and pharmaceutical compositions comprising these, all for use in the treatment of chemokine mediated diseases and disorders.

Abstract: This invention relates to a method of preparing mesylate salts of compounds that inhibit IL-12, IL-23 and/or IL-27 production.

Abstract: Stable, topically applicable cosmetic/dermatological sunscreen compositions, well suited for the UV-photoprotection of human skin/keratinous materials, contain a thus effective amount of at least one novel s-triazine compound bearing at least one para-aminobenzalmalonic salt substituent.

Abstract: Disclosed are triazine derivatives of formula X1 is a bivalent radical of formula A and A? independently from each other are unsubstituted or substituted, straight-chain or branched C1-C12alkylene, which is optionally interrupted by C5-C12cycloalkylene, N, O or S; C5-C12cycloalkylene; biphenylene; C6-C10arylene; or C5-C10arylene-(C1-C12alkylene); R1 is a radical of formula R2 and R3 independently from each other are hydrogen; C1-C12alkyl; OR7; NR7R8; C6-C10aryl; X2 is O, or NH; W1 is C1-C20alkyl; or a group Sp-Sil; Sp is a straight-chain or branched saturated or single or multiple unsaturated C3-C12 hydrocarbon; Sil is a silane; an oligosiloxane; or a polysiloxane moiety; and R4, R5 R6, R7, R8 and R9 independently from each other are hydrogen; C1-C12alkyl; or C3-C12cycloalkyl.

Abstract: 1-Arylpyrazole-3-substituted-amidoxime derivatives of formula (Ia) or (Ib): or salts thereof, wherein the various symbols are as defined in the description, and pesticidal compositions thereof, processes for their preparation, and methods for their use for the control of arthropods (including insects and arachnids) and helminths (including nematodes).

Abstract: The present invention is directed towards a process for resolving a racemic amino compound derived from dihydro-1,3,5-triazines. The invention is also directed towards the enantiomers of amino derivatives of dihydro-1,3,5-triazines and to their use for the preparation of medicaments, in particular for the treatment of diabetes and malaria.

Abstract: The present invention relates to a bridge compound with N,N-dialkylamino group, represented by the following formula (I), wherein, R, R?, R?, R1, R2, B, B?, i, j, m, and n are defined the same as the specification. The novel bridge compound of the present invention is suitable for being used as a bridge group between dyestuffs, ultraviolet absorbers, or one dyestuff and one ultraviolet absorber. In addition, the present invention further provides a dyestuff compound provided from the aforementioned bridge compound.

Abstract: The invention provides compounds of formula (1), and the pharmaceutically acceptable salt thereof, wherein R1, n and R2 are as described herein; compositions thereof; and uses thereof.